Postherpetic Neuralgia Clinical Trial Pipeline Analysis: 3+ Key Companies Shaping the Future of Postherpetic Neuralgia Therapeutics | DelveInsight

DelveInsight's Postherpetic Neuralgia Pipeline Insight 2026 report provides comprehensive global coveannarage of available, marketed, and pipeline Postherpetic Neuralgia therapies in various stages of clinical development. The report provides insights into 3+ companies and 3+ pipeline drugs in the Postherpetic Neuralgia pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the Postherpetic Neuralgia Clinical Trial Landscape Report

• DelveInsight's Postherpetic Neuralgia pipeline report depicts a developing space with 3+ companies working to develop 3+ pipeline therapies for Postherpetic Neuralgia treatment.
• Key Postherpetic Neuralgia companies such as Ono Pharmaceutical Co. Ltd, Undaunted Bio, INC, Shanghai SIMR Biotechnology Co., Ltd.
• Promising Postherpetic Neuralgia pipeline therapies in various stages of development include ONO-1110, UDB412, and SR419.

Request a sample and discover the recent advances in Postherpetic Neuralgia treatment drugs https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Postherpetic Neuralgia?

Postherpetic neuralgia (PHN) is a common and painful complication that occurs after a shingles outbreak, caused by the reactivation of the varicella-zoster virus (VZV). It is characterized by persistent, burning or lancinating pain along a specific dermatomal pattern that lasts for months after the rash heals. The elderly and immunocompromised individuals are particularly at risk, with age and weakened immune systems being key risk factors.
Postherpetic Neuralgia primarily affects the skin area where the shingles rash occurred, often in a band around the trunk on one side of the body. Symptoms include persistent pain that lasts for three months or more after the rash has healed, which can be burning, sharp, jabbing, or deep and aching. Many individuals with PHN also experience heightened sensitivity, where even light touch, such as clothing on the skin, becomes unbearable. Additionally, some people may experience itching or numbness in the affected area.
The exact cause of Postherpetic Neuralgia is not fully understood, but it appears to involve both peripheral and central nervous system changes. Immune system activation, persistence of viral particles in nerve ganglia, nerve damage, inflammation, and central sensitization are believed to contribute to the development of the condition.
Treatment involves prevention, early treatment of acute herpes zoster, and symptom management. First-line treatments include oral tricyclic antidepressants, pregabalin, and the lidocaine 5% patch. Other options include capsaicin patches, NMDA antagonists, botulinum toxin, epidural injections, spinal cord stimulation, physical therapy, cognitive-behavioral therapy, acupuncture, and transcutaneous electrical nerve stimulation.

Emerging Postherpetic Neuralgia Drug Profiles

ONO-1110: Ono Pharmaceutical Co. Ltd
ONO-1110 is an investigational drug currently undergoing development for Postherpetic Neuralgia (PHN). This drug targets the regulation of endogenous distinguishing it from traditional based treatments. While medical marijuana has been shown to provide some relief for pain and depression, it often comes with undesirable side effects such as euphoria and somnolence.
ONO-1110 aims to harness the therapeutic benefits of without these drawbacks, offering a promising alternative for managing PHN and other diseases. The drug is undergoing clinical trials in Japan, which are evaluating its potential to provide pain relief and other pharmacological benefits with fewer side effects compared to traditional treatments. Currently, the drug is in the Phase II stage of development for the treatment of Postherpetic Neuralgia.

UDB412: Undaunted Bio, INC
UDB412 is a repurposed drug that Undaunted Bio is reformulating into an Oral Thin Film for the treatment of pain in Trigeminal Neuralgia patients. UDB412 is being developed via the FDA's 505(b)(2) pathway as a reformulation of the original tablet form into an oral thin film (OTF). The OTF dissolves quickly on the tongue, without the need for water, and is designed to enable patients to take their medication even during an attack of Trigeminal Neuralgia, potentially improving the management of their pain. Currently, the drug is in the Discovery stage of development for the treatment of Postherpetic Neuralgia.

SR419: Shanghai SIMR Biotechnology Co., Ltd.
SR419 is an emerging pipeline therapy being developed by Shanghai SIMR Biotechnology Co., Ltd. for Postherpetic Neuralgia. It is among the key products included in DelveInsight's Postherpetic Neuralgia pipeline landscape.

Learn more about the novel and emerging Postherpetic Neuralgia pipeline therapies https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Postherpetic Neuralgia Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key Postherpetic Neuralgia Companies: Ono Pharmaceutical Co. Ltd, Undaunted Bio, INC, Shanghai SIMR Biotechnology Co., Ltd.
• Key Postherpetic Neuralgia Pipeline Therapies: ONO-1110, UDB412, SR419

Dive deep into rich insights for new drugs for Postherpetic Neuralgia treatment, visit https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Postherpetic Neuralgia Pipeline Report Introduction
2. Postherpetic Neuralgia Pipeline Report Executive Summary
3. Postherpetic Neuralgia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Postherpetic Neuralgia Pipeline Therapeutics
6. Postherpetic Neuralgia Pipeline: Late Stage Products (Phase III)
7. Postherpetic Neuralgia Pipeline: Mid Stage Products (Phase II)
8. Postherpetic Neuralgia Pipeline: Early Stage Products (Phase I)
9. Postherpetic Neuralgia Pipeline: Preclinical and Discovery Stage Products
10. Postherpetic Neuralgia Pipeline Therapeutics Assessment
11. Inactive Products in the Postherpetic Neuralgia Pipeline
12. Key Companies
13. Key Products in the Postherpetic Neuralgia Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Postherpetic Neuralgia pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: DelveInsight

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe.

This release was published on openPR.